Clinical Trials
25 trialsNCT04126070 2026-05-27
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07609251 2026-05-27
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
Sinocelltech Ltd.
Phase 2 Not yet recruiting
NCT00334815 2026-05-26
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06780098 2026-05-26
MK-3475-01I
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05800587 2026-05-22
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05848011 2026-05-22
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
Phase 2 Completed
NCT07601737 2026-05-22
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT04329065 2026-05-19
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06783647 2026-05-18
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT01350817 2026-05-15
TARSEQ
University Hospital, Limoges
Phase 2 Completed
NCT04001829 2026-05-15
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06618014 2026-05-15
NeoTOP
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07415031 2026-05-15
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT04310007 2026-05-13
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05836584 2026-05-13
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06445400 2026-05-13
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT05541016 2026-05-12
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Mayo Clinic
Phase 2 Recruiting
NCT05631262 2026-05-08
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT07220135 2026-05-06
NeoTHERa
University of Kansas Medical Center
Phase 2 Recruiting
NCT07287150 2026-05-06
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT03493425 2026-05-05
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT04266249 2026-05-05
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05005728 2026-05-05
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting